On November 13, HeartFlow Inc fell 6.04% in After-Hours Trading, trading at $56.33/share, with turnover of $7.9693 million.
The move followed the company’s third-quarter earnings release, even though reported results came in ahead of expectations and full-year revenue guidance was raised.
HeartFlow Inc reported adjusted EPS of $(0.03), better than the $(0.10) consensus estimate, while revenue rose 57% year over year to $72.857 million, above the $65.264 million expectation. Net loss narrowed 77% to $11.51 million, driven primarily by higher U.S. FFRCT and Plaque case volumes. The company also lifted full-year revenue guidance to $262 million-$264 million from $246 million-$250 million, above the $248.6 million market expectation. Recent clinical updates had also supported sentiment, including data showing HeartFlow Plaque Analysis was associated with 34% fewer major cardiovascular events and a randomized PCI planning trial that met its primary endpoint.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments